TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04449952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula
Description: Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush teeth at least one minute with provided bristled toothbrush.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush teeth at least one minute with provided bristled toothbrush.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush teeth at least one minute with provided bristled toothbrush.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Floss
Description: Participants will use marketed fluoride-containing dentifrice, floss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Floss
Description: Participants will use marketed fluoride-containing dentifrice, floss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Floss
Description: Participants will use marketed fluoride-containing dentifrice, floss.
Study: NCT02346331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO algorithm of fluid boluses guided by physical examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent patient monitoring
Description: Vital signs and physical exam every 30-60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early administration of empiric antibiotics
Description: Clinician will be prompted to administer antibiotics within 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of hypoglycemia
Description: If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of severe anemia
Description: If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
Study: NCT00616811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT01472783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
Study: NCT01791881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hugeltox
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hugeltox
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A(Botox®)
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A(Botox®)
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
Study: NCT00473967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2 Hookworm Vaccine
Description: Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Na-ASP-2 Hookworm Vaccine
Description: Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
Study: NCT02616497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: COX-1 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triflusal
Description: COX-1 inhibitor
Study: NCT01568151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-directed intervention program
Description: Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Patient-Directed Program
Description: If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
Study: NCT01432145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: 6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
Study: NCT03752346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes.
Study: NCT00202709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (TFT)
Description: Treatment with TFT twice in one week
Study: NCT04039711

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal self-sampling
Description: The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
Study: NCT01322399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Structural Integration
Description: Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
Study: NCT03457142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Given IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01398332

Intervention type: DEVICE
Intervention: Stent graft (EXCLUDER)
Description: Endovascular repair
Study: NCT00132691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluocinolone acetonide intraocular implant
Description: RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral corticosteroid with immunosuppressive agents as needed
Description: Prednisone
Study: NCT01792817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaCore
Description: Treatment with active gammacore vagus nerve stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham GammaCore device
Description: Treatment with sham stimulator
Study: NCT02226562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium nitrate and sodium fluoride
Description: 3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride

Intervention type: DRUG
Group type: OTHER
Intervention: Standard fluoride dentifrice
Description: Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
Study: NCT03006029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
Study: NCT03758079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin
Description: 10 mg Doxepin for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
Study: NCT00961246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health information
Description: participants received general health information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individually-tailored intervention
Description: participants received individually-tailored intervention
Study: NCT01413100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study: NCT00865124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg capsule daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide + potassium
Description: hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily
Study: NCT00853801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and provider feedback
Description: Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months.
Study: NCT02335294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Description: Rescue: Ibuprofen, oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Rescue: Ibuprofen, oxycodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rescue: Ibuprofen, oxycodone
Study: NCT02598076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard psychotherapy
Description: Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard psychotherapy
Description: Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
Study: NCT00352144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00159536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Study: NCT03251768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHSA-GCSF 2.4mg
Description: Human Serum Albumin GCSF 2.4mg at day 3 and day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCSF
Description: GCSF 5 mcg/kg/day
Study: NCT00298220

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Feedback about patients at risk
Description: GPTs receive this feedback about their patient population; obtained through premeasurement results

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback about patients at risk
Description: GPTs receive this feedback about their patient population; obtained through premeasurement results

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Dissemination guideline and patient information letters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dissemination guideline and patient information letters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored educational training
Description: for GP(T)s

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored outreach based facilitator support
Description: in the practices of the GPTs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitation of co-operation with local addiction services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient directed interventions
Description: Like poster for the waiting room, self-help booklets, folders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder-card for GP's desk

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Personal feedback to patients
Description: Patients receive advise based on their premeasurement answers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal feedback to patients
Description: Patients receive advise based on their premeasurement answers
Study: NCT02256228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Active Group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Comparator
Study: NCT03485768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous disc decompression with coblation nucleoplasty
Description: PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy (SNAGs plus PJMs)
Description: (1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary.
Study: NCT00638768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
Study: NCT03813472

Intervention type: DEVICE
Intervention: Hydration Sensor
Description: This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.

Intervention type: DEVICE
Intervention: Hydration Sensor
Description: This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
Study: NCT01413100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00570791

Intervention type: DEVICE
Intervention: Tonometer
Description: Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer

Intervention type: DEVICE
Intervention: Tonometer
Description: Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
Study: NCT03368963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT03658200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FAST start software delay
Description: Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual bolus tracking delay
Description: Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
Study: NCT03102047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)